Figure 2From: Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing Percentage of subjects with plasma hydromorphone concentrations ≥50% Cmax at each time point after dosing with OROS hydromorphone ER and IR hydromorphone. Panels show percentages after single dosing (a) and at steady state (b). Cmax, maximum plasma concentration; ER, extended-release; IR, immediate-release.Back to article page